The Impact of Liver Metastasis on Mortality in Patients Initially Diagnosed with Locally Advanced or Resectable Pancreatic Cancer

Overview

Journal Int J Gastrointest Cancer

Date 2004 Jan 13

PMID 14716065

Citations 6

Authors

Chigusa Nakahashi

Tatsuya Oda

Taira Kinoshita

Takanori Ueda

Masaru Konishi

Toshio Nakagohri

Kazuto Inoue

Junji Furuse

Atsushi Ochiai

Nobuhiro Ohkohchi

Affiliations

Soon will be listed here.

Abstract

Background: Liver metastases are frequent in pancreatic cancer, although their impact on patient mortality is still unclear.

Method: The extent of liver metastasis (H-III [diffuse], H-II [moderate], H-I [limited], H-0) and the magnitude of liver dysfunction (lf-III [failure], lf-II [severe], lf-I [moderate], lf-0) were reviewed in 89 locally advanced and resectable pancreatic cancer patients in order to determine possible relationships with mortality and survival.

Results: The extent of liver metastasis (H-III, 18; H-II, 20; H-I, 12; H-0, 39) and the magnitude of liver dysfunction (lf-III, 12; lf-II, 8; lf-I, 11; lf-0, 58) were quite variable. Based on the aforementioned two categories, pancreatic cancer patients could be divided into four groups: (A) extensive liver metastasis affecting patient mortality, 14% (12/89); (B) liver metastases that do not cause severe liver dysfunction, 38% (34/89); (C) severe liver dysfunction, not associated with liver metastasis, 9% (8/89); (D) spared liver function, with no liver metastasis, 39% (35/89). The median survival period of H-III patients (195 d) was quite short compared with those of H-I (288 d) and H-0 (240 d) patients.

Conclusion: Considering patients with locally advanced and resectable pancreatic cancer, the fraction of cases with diffuse liver metastases is relatively small. Moreover, only a minor proportion of pancreatic cancer patients die from hepatic failure as a direct result of liver metastasis.

Citing Articles

Causes of Death Among Patients With Initially Inoperable Pancreas Cancer After Induction Chemotherapy and Ablative 5-fraction Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy.

Chuong M, Herrera R, Ucar A, Aparo S, De Zarraga F, Asbun H Adv Radiat Oncol. 2022; 8(1):101084.

PMID: 36483070 PMC: 9723297. DOI: 10.1016/j.adro.2022.101084.

An integrative theory for cancer (Review).

Luo G, Liu N Int J Mol Med. 2018; 43(2):647-656.

PMID: 30483756 PMC: 6317675. DOI: 10.3892/ijmm.2018.4004.

Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern.

Kim H, Lee J, Paik K, Kang J, Kim J, Hwang J Medicine (Baltimore). 2017; 96(5):e5926.

PMID: 28151872 PMC: 5293435. DOI: 10.1097/MD.0000000000005926.

Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Shi H, Li J, Fu D J Cancer Res Clin Oncol. 2015; 142(6):1137-61.

PMID: 26250876 DOI: 10.1007/s00432-015-2024-0.

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Iacobuzio-Donahue C, Fu B, Yachida S, Luo M, Abe H, Henderson C J Clin Oncol. 2009; 27(11):1806-13.

PMID: 19273710 PMC: 2668706. DOI: 10.1200/JCO.2008.17.7188.

References

Mao C, Domenico D, Kim K, Hanson D, Howard J . Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 1995; 130(2):125-34. DOI: 10.1001/archsurg.1995.01430020015001. View

Warshaw A, Fernandez-Del Castillo C . Pancreatic carcinoma. N Engl J Med. 1992; 326(7):455-65. DOI: 10.1056/NEJM199202133260706. View

Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K, Matsuno S . Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Br J Surg. 1999; 87(1):43-8. DOI: 10.1046/j.1365-2168.2000.01336.x. View

Costa G . Cachexia, the metabolic component of neoplastic diseases. Cancer Res. 1977; 37(7 Pt 2):2327-35. View

Bengmark S, Hafstrom L . The natural history of primary and secondary malignant tumors of the liver . II. The prognosis for patients with hepatic metastases from gastric carcinoma verified by laparotomy and postmortem examination. Digestion. 1969; 2(3):179-86. DOI: 10.1159/000196936. View

Ishikawa O, Ohigashi H, Imaoka S, Sasaki Y, Iwanaga T, Matayoshi Y . Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head?. Arch Surg. 1994; 129(10):1075-80. DOI: 10.1001/archsurg.1994.01420340089017. View

TREY C, Burns D, SAUNDERS S . Treatment of hepatic coma by exchange blood transfusion. N Engl J Med. 1966; 274(9):473-81. DOI: 10.1056/NEJM196603032740901. View

Ishikawa O, Ohigashi H, Sasaki Y, Furukawa H, Kabuto T, Kameyama M . Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg. 1994; 168(4):361-4. DOI: 10.1016/s0002-9610(05)80167-9. View

Pugh R, Murray-Lyon I, Dawson J, Pietroni M, Williams R . Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60(8):646-9. DOI: 10.1002/bjs.1800600817. View

10.

Michelassi F, Erroi F, Dawson P, Pietrabissa A, Noda S, Handcock M . Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg. 1989; 210(4):544-54; discussion 554-6. PMC: 1357942. DOI: 10.1097/00000658-198910000-00015. View

11.

Moriwaki H, Naito T . [Fulminant hepatitis: diagnostic standard and the extent of severity]. Nihon Naika Gakkai Zasshi. 1999; 88(4):640-6. View

12.

Christensen E, Schlichting P, Fauerholdt L, Juhl E, POULSEN H, Tygstrup N . Changes of laboratory variables with time in cirrhosis: prognostic and therapeutic significance. Hepatology. 1985; 5(5):843-53. DOI: 10.1002/hep.1840050523. View

13.

Takada T, Yasuda H, Amano H, Yoshida M, Uchida T . Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival?. Hepatogastroenterology. 1997; 44(14):567-73. View

14.

Tisdale M . Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition. 1997; 13(1):1-7. DOI: 10.1016/s0899-9007(96)00313-9. View

15.

Douglass Jr H, Penetrante R . Pancreatic cancer. Why patients die. Int J Pancreatol. 1990; 7(1-3):135-40. DOI: 10.1007/BF02924230. View

16.

Tisdale M . Biology of cachexia. J Natl Cancer Inst. 1997; 89(23):1763-73. DOI: 10.1093/jnci/89.23.1763. View

17.

OGrady J, Alexander G, Hayllar K, Williams R . Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989; 97(2):439-45. DOI: 10.1016/0016-5085(89)90081-4. View

18.

Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K . Collective review of small carcinomas of the pancreas. Ann Surg. 1986; 203(1):77-81. PMC: 1251042. DOI: 10.1097/00000658-198601000-00013. View

19.

Inagaki J, Rodriguez V, Bodey G . Proceedings: Causes of death in cancer patients. Cancer. 1974; 33(2):568-73. DOI: 10.1002/1097-0142(197402)33:2<568::aid-cncr2820330236>3.0.co;2-2. View

20.

Von Meyenfeldt M . Nutritional support during treatment of biliopancreatic malignancy. Ann Oncol. 1999; 10 Suppl 4:273-7. View